FOLH1 and prostate carcinoma: [177Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer (LuPSMA trial): A Single-Centre, Single-Arm, Phase 2 study [29]